Legal updates and opinions
News / News
Compensation for employees who experience injuries, illness or death as a result of the Covid-19 vaccine
Compensation for Occupational Injuries and Diseases Act 130 of 1993
by Jacques van Wyk, Director and Andre van Heerden, Senior Associate
On 22 October 2021, a notice was published in the Government Gazette in terms of section 6A(b) of the Compensation for Occupational Injuries and Diseases Act 130 of 1993 (“COIDA“). The notice relates to the compensation for side effects to the Covid-19 vaccination (“Notice“) based on employees who experience injuries, illness or death as a result of the Covid-19 vaccine in the circumstances where the requirement to have the vaccine is an inherent requirement of the employee’s job or where the employee is required to do so in terms of his/her employer’s risk assessment.
Read our article discussing vaccination policies for the workplace for more on the implementation of a mandatory vaccination policy and the required risk assessment).
The Notice provides that if an employee is required to receive a Covid-19 vaccine, either as a result of an occupational health and safety risk assessment conducted by an employer or where the vaccine is an inherent requirement of employment, any injury, illness or death incurred as a result will be covered by the Compensation Fund.
However, in order for such cover to extend to an employee, there are 6 requirements that apply:
- The vaccine must be regarded as an inherent requirement of employment in terms of the employer’s risk assessment;
- The employee must have received a SAHPRA-approved Covid-19 vaccine;
- Evidence of the employer’s risk assessment and vaccination plan in terms of the Consolidated Directions on Occupational Health and Safety Measures in Certain Workplaces must be provided;
- The chronological sequence between the vaccine inoculation and the development of the employee’s symptoms and clinical signs must be provided;
- The employee must have presented with symptoms and clinical signs that are generally recognised as side effects of the Covid-19 vaccine; and
- Additional tests may be required to assess the presence of abnormalities of any organ affected.
A copy of the Notice can be accessed here.
Latest News
The union doth protest too much: NUMSA v BMW and the limits of court intervention in disciplinary proceedings
by Bradley Workman-Davies, Director The Labour Court’s judgment in NUMSA on behalf of Members v BMW (SA) (Pty) Ltd is [...]
Evaluating the public interest effects of a merger: The Competition Appeal Court charts the course
by Paul Coetser, Director and Head of Competition and Kwanele Diniso, Associate When evaluating a merger, the Competition Act 89 [...]
What makes the “Best” mobile network? A South African perspective
by Ahmore Burger-Smidt, Director and Head of Regulatory Choosing the “best” mobile network depends on multiple factors. In practice, it [...]
South African Competition Commission’s Draft Guidelines on Minority Shareholder Protections: what businesses need to know
by Ahmore Burger-Smidt, Director and Head of Regulatory The Competition Commission has published Draft Guidelines on Minority Shareholder Protections for [...]
COMESA publishes important new Competition Regulations
by Paul Coetser, Director and Head of Competition and Raisah Mahomed, Associate The Common Market for Eastern and Southern Africa [...]
Supreme Court of Appeal clarifies boundaries between casino and bookmaker licences in the Gauteng province
by Wendy Rosenberg - Director, Tebogo Sibidla - Director and Nothando Madondo - Associate In recent years, the number of [...]
